£16 – £89.99

CUTEC Technology Ventures Conference 15th Anniversary

Event Information

Share this event

Date and Time



Department of Engineering, University of Cambridge

Trumpington Street



United Kingdom

View Map

Refund Policy

Refund Policy

No Refunds

Event description


Join CUTEC for the 15th Annual Technology Ventures Conference

Impact of biotech on the future of healthcare

The biggest student-run technology entrepreneurship conference in the UK


Advances in the field of biotech are bound to revolutionise healthcare as we know it. This year, the TVC looks at the future of healthtech and explores how technology can impact prevention, diagnosis, treatment and disease management. Come and explore the disruptive capabilities these developing technologies offer Entrepreneurs and established Businesses at the 15th annual Technology Ventures Conference.

The Technology Ventures Conference is the biggest student-run technology entrepreneurship conference in the UK, hosted by the Cambridge University Technology and Enterprise Club. The TVC brings together over 300 Entrepreneurs, Researchers, Professionals, Investors, and Students in an annual one-day event to encourage the melding of knowledge and ideas.

Catering, coffee and tea included in the ticket price

Speakers and Events

Chris Lowe

Cambridge Academy of Therapeutic Sciences - Director

Professor Christopher R. Lowe was founder Director of the Institute of Biotechnology at the University of Cambridge and conducts research in both diagnostics and therapeutics in the healthcare biotechnology sector. He has been the driving force for the establishment of 11 spin-out companies including ProMetic Biosciences Inc (Market Cap $1.9-2.1B), Cambridge Sensors Ltd, Paramata Ltd, Psynova Neurotech Ltd and Royale Therapeutics Ltd., has a number of directorships and fosters entrepreneurship within the University via a Master’s in Bioscience Enterprise, the University’s Seed Fund Committee (Cambridge Enterprise) and other Business School and student-led activities. He is currently Director of the newly established Cambridge Academy of Therapeutic Sciences (CATS) within the University of Cambridge.

Iain Buchan

Microsoft NExT - Director of Healthcare Research

Iain is Director of Healthcare Research at Microsoft Research, in Cambridge (UK), and part of the Leadership Team for Healthcare NExT, an initiative that aims to transform healthcare through empowering patients, clinicians, practitioners and provider organisations, in healthcare systems that achieve more for everyone. He is a world leader in using data and technology in public health. In his keynore titled "AI for Higher Definition Healthcare", he will challenge the current stampede into data-led healthcare AI, suggesting instead a problem-led approach. Professor Buchan will explore how higher definition healthcare might be delivered at scale through a network of health systems that each have three interlocking quality improvement feedback loops, supported by AI: self-care personalisation; health worker augmentation; and health system adaptation/learning.

Heather Fraser

IBM - Global Life Sciences and Healthcare Lead

Heather is the global lead for the Life Sciences and Healthcare in the IBM Institute for Business Value (the business think tank of IBM). In this role, she and her team research and develop thought leadership on many industry-specific business issues.

Laurent Morlet

Johnson & Johnson Innovation - Technology Director Value Creation Medical Devices

Laurent’s primary responsibility is to develop and execute an Innovative Technology Strategy and Roadmap that enhances J&J MD position as the partner of choice and ensures Technology is in place to enable commercial opportunities that drive profitable growth. Most recently Laurent was Healthcare Technology New Ventures at the London Innovation Centre where he was responsible for driving J&J Innovation digital health strategy through the identification and development of investment opportunities in EMEA.

Anna Williamson

Genentech - Business Development

While at Genentech, Anna has developed strategic collaborations with academic institutions and with companies such as Curis, Sangamo, Abbott and Symphogen. Prior to joining Genentech in 2004, Anna worked at the University of California Office of Technology Transfer where she was responsible for managing and out-licensing a portfolio of life sciences inventions from multiple UC campuses.

Professor Rebecca Fitzgerald

Cancer Research UK - Professor of Cancer Prevention

​Professor Rebecca Fitzgerald, based at the MRC Cancer Unit at the University of Cambridge , is head of a research group that studies oesophageal cancer. Despite progress in cancer research, the outlook for patients with this hard-to-treat cancer remains poor because it is often diagnosed late. Finding new ways to catch the disease earlier is therefore important to improve survival, and is the focus of this group’s research.

Tim Guilliams

Healx - Founder & CEO

Tim is a social entrepreneur passionate about delivering the next generation of therapeutics to rare disease patients in need. He is the Founder and Chief Executive of Healx and the Co-Founder and Chair of the Cambridge Rare Disease Network (CRDN), a charity aiming to foster dialogue and awareness around rare diseases in Cambridge, UK. He is also a Junior Associate Fellow of the Centre for Science and Policy (CSaP).

Hamish Grierson

Thriva - Founder & CEO

Thriva started in 2016 with the aim of building the world's first preventative health service. There is no simple and convenient way to track what's really going on inside your body which means most people are forced to wait until something goes wrong until they can react - Hamish Grierson wants to change that with Thriva.

Keiron Sparrowhawk

MyCognition - Founder & CEO

Keiron founded MyCognition, which was born from seeing someone playing a video game while having an MRI scan and seeing different parts of the brain light up, indicative of neuronal pathways being fired-up. This showed that neuroplasticity could be encouraged through targeted stimulation, leading to behavioural and health benefits.

Henry Farmery

Cambridge Cancer Genomics - Bioinformatician

Cambridge Cancer Genomics is using blood tests to guide smarter cancer therapy. Currently, cancer patients have to wait up to 6 months to know whether their chemotherapy is working. In the interim, patients suffer the side effects of such treatments. Using simple blood draws, CCG shortens the time required to know whether treatment is working, buying the clinician more time to alter treatment and reduce unnecessary side effects. In addition, we can identify relapse an average of 7 months earlier than standard practice. Over time, CCG will be able to better predict the best therapeutic strategy for cancer patients before they even begin treatment.

Jaime Domingues

Benevolent AI - Founder & CEO

BenevolentAI was founded in 2013 by Ken Mulvany following the sale of Proximagen, a successful biotech business that Ken founded. Jaime Domingues will be talking the exerpience of BenevolentAI in disrupting drug discovery and healthcare.

Mahyar Salek

DeepCell - Founder & CTO

Mahyar is a co-founder and CTO of Deepcell, an award winning venture-funded biotech startup in Sunnyvale California. Prior to Deepcell, he was the lead product manager at Google for their Store Visits product. During his tenure, the product grew from beta at an explosive rate to a mature market leading product with a multi-billion dollar impact. He was a former officer of CUTEC during the time that he was a post-doc researcher at Microsoft Research Cambridge. His prior entrepreneurial experience included building Emotiful, a social photo tagging app which got featured on several platforms as a top ranking app due to its rapid user growth and positive reception.

Nick Taylor

Unmind - CEO

Nick started his journey in mental health as a Support Worker for Mind and volunteer Samaritan, both of which instilled a lifelong passion for supporting others. After many years of studying he qualified as a Clinical Psychologist going on to work in a variety of frontline NHS services. In 2016 he left to create Unmind - a mental health solution for businesses that empowers employees, via a digital platform, to take positive and proactive steps towards improving their mental health. Unmind's platform is now live with a wide range of household name clients and used everyday by thousands of employees across the UK.

Neil Dealy

Skin Analytics - CEO

Neil founded Skin Analytics in 2012, having previously deployed mobile financial services across emerging markets before moving into digital health on projects with organisations like J&J. Neil has a BSc in Physics and Mathematics from the University of Western Australia and an Executive MBA from London Business School.

And more to be announced, plus workshops and break-out sessions... check out our website for updates:


VIP Dinner

Following tradition we will have a pre-dinner drinks reception and three-course VIP dinner, this year at Double Tree by Hilton Cambridge, the night of the conference, Wednesday June 20th at 7:30

Dinner is included for professionals ticket. For other ticket types, please select the option with dinner if you wish to attend. Dietary requirements can be specified here: https://goo.gl/forms/TrwUpSs5pMfiWN1m2

Share with friends

Date and Time


Department of Engineering, University of Cambridge

Trumpington Street



United Kingdom

View Map

Refund Policy

No Refunds

Save This Event

Event Saved